Research Group in Neuroscience and Experimental Psychology, Petrolina, Pernambuco, Brazil.
Postgraduate Program in Psychology, Federal University of Vale do São Francisco (UNIVASF), Petrolina, Brazil.
Int J Neurosci. 2023 Dec;133(12):1319-1325. doi: 10.1080/00207454.2022.2079501. Epub 2022 May 31.
: Dopamine replacement therapy with levodopa is the gold standard treatment of Parkinson's disease (PD); however long-term levodopa use is associated with abnormal involuntary movements known as levodopa-induced dyskinesia (LID) in most patients. LID is not preventable and represents the major limitation of PD treatment.: This study was aimed to find clinical and behavioral features that could be used to identify, years in advance, PD patients that are at high risk of developing LID in the future. : Data from PD patients enrolled in (PPMI, Michael J. Fox Foundation) that developed dyskinesia during their participation in the study were compared with those who did not, and with healthy controls.: LID was preceded byhigher levels of trait anxiety and increased motor impairment in PD patients. Additionally, younger age at PD diagnosis, earlier need for dopaminergic therapy and higher initial levodopa dose, were associated with future development of dyskinesia.: These findings suggest that easily detectable clinical and behavioral alterations may help to identify PD patients that are more susceptible to develop LID.
: 多巴胺替代疗法左旋多巴是治疗帕金森病 (PD) 的金标准；然而，大多数患者长期使用左旋多巴会导致异常不自主运动，称为左旋多巴诱导的运动障碍 (LID)。LID 不可预防，是 PD 治疗的主要限制因素。: 本研究旨在寻找可用于提前数年识别 PD 患者未来发生 LID 风险较高的临床和行为特征。: 比较了在 (PPMI，Michael J. Fox 基金会) 中出现运动障碍的 PD 患者与未出现运动障碍的患者以及健康对照组的数据。: 在出现 LID 之前，PD 患者的特质焦虑水平更高，运动障碍更严重。此外，PD 诊断年龄越小、对多巴胺能治疗的需求越早以及初始左旋多巴剂量越高，与日后出现运动障碍有关。: 这些发现表明，容易检测到的临床和行为改变可能有助于识别更容易发生 LID 的 PD 患者。
